Published on 19 Feb 2024 on Simply Wall St. via Yahoo Finance
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Estimates
One thing we could say about the analysts on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured majorly on the business. Shares are up 5.4% to US$26.51 in the past week. Investors could be forgiven for changing their mind on the business following the downgrade; but it's not clear if the revised forecasts will lead to selling activity.
After the downgrade, the nine analysts covering Agios Pharmaceuticals are now predicting revenues of US$43m in 2024. If met, this would reflect a sizeable 79% improvement in sales compared to the last 12 months. Per-share losses are expected to explode, reaching US$5.80 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$71m and losses of US$5.20 per share in 2024. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts.
View our latest analysis for Agios Pharmaceuticals